3'OMe-m7GpppAmpG Tris
3'OMe-m7GpppAmpG (Tris) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3'OMe-m7GpppAmpG (Tris) effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3'OMe-m7GpppAmpG (Tris) is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research.
For research use only. We do not sell to patients.
- Formula: C45H78N18O33P4
- Molecular Weight:1523.10
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
3'OMe-m7GpppAmpG (Tris) (4 mM; 2 h) supports the production of translationally active HA-encoding mRNA that expresses functional HA protein in HEK293 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 1523.10
-
Formula C45H78N18O33P4
-
SMILES
OCC(CO)([NH3+])CO.OCC(CO)([NH3+])CO.OCC(CO)([NH3+])CO.NC1=NC=NC2=C1N=CN2[C@H]3[C@H](OC)[C@H](OP(OC[C@H]4O[C@@H](N(C=N5)C6=C5C(NC(N)=N6)=O)[C@H](O)[C@@H]4O)([O-])=O)[C@@H](COP(OP(OP(OC[C@H]7O[C@@H](N(C=[N+]8C)C9=C8C(NC(N)=N9)=O)[C@H](O)[C@@H]7OC)([O-])=O)([O-])=O)([O-])=O)O3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)